biostudies-literatureChen CDNCATS NIH HHSNIA NIH HHSNINDS NIH HHSNIHNIH HHS2669-2682https://www.ebi.ac.uk/biostudies/studies/S-EPMC10330155biostudies-literatureUnknown50(9)<h4>Purpose</h4>Pittsburgh Compound-B (¹¹C-PiB) and ¹⁸F-florbetapir are amyloid-β (Aβ) positron emission tomography (PET) radiotracers that have been used as endpoints in Alzheimer's disease (AD) clinical trials to evaluate the efficacy of anti-Aβ monoclonal antibodies. However, comparing drug effects between and within trials may become complicated if different Aβ radiotracers were used. To study the consequences of using different Aβ radiotracers to measure Aβ clearance, we performed a head-to-head comparison of ¹¹C-PiB and ¹⁸F-florbetapir in a Phase 2/3 clinical trial of anti-Aβ monoclonal antibodies.<h4>Methods</h4>Sixty-six mutation-positive participants enrolled in the gantenerumab and placebo arms of the first Dominantly Inherited AlzheimeEuropean journal of nuclear medicine and molecular imagingLongitudinal head-to-head comparison of &lt;sup&gt;11&lt;/sup&gt;C-PiB and &lt;sup&gt;18&lt;/sup&gt;F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's disease.PMC10330155K01 AG080123R01 AG052550R01AG53267-S1UF1 AG032438T32 AG058518RF1 AG073424UL1 TR001863P30 AG072980U01AG042791U01 AG042791U19 AG032438P30NS098577U01AG042791-S1R01AG052550-01A1P30 AG066508R01 AG053267P30 AG066462P30 NS098577R01 AG068319U19AG032438S10 OD025214R01 AG046179R01AG046179Klunk WEGauthier SBrooks WSFagan AMWang GBateman RJHobbs DAHiggins IShi XBerman SBKoeppe RGalasko DWallon Dvan Dyck CHDubois BSu YTunali IBrosch JChen CDClarnette RMasellis MJack CCruchaga CLi YMcKay NSJimenez-Velazquez IZFlores SXiong CShcherbinin SMills SPariente JHornbeck RSnider BJSalloway SSurti GDIAN-TU Study TeamRoberson EDSupnet-Bell CPasquier FHsiung RHonig LSPontecorvo MJGoate AMPerrin RJClifford DBJoseph-Mathurin NMasters CLMcDade EKlein GMcCullough ASanchez-Valle RBenzinger TLSGordon BfalseLongitudinal head-to-head comparison of &lt;sup&gt;11&lt;/sup&gt;C-PiB and &lt;sup&gt;18&lt;/sup&gt;F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's disease.<h4>Purpose</h4>Pittsburgh Compound-B (¹¹C-PiB) and ¹⁸F-florbetapir are amyloid-β (Aβ) positron emission tomography (PET) radiotracers that have been used as endpoints in Alzheimer's disease (AD) clinical trials to evaluate the efficacy of anti-Aβ monoclonal antibodies. However, comparing drug effects between and within trials may become complicated if different Aβ radiotracers were used. To study the consequences of using different Aβ radiotracers to measure Aβ clearance, we performed a head-to-head comparison of ¹¹C-PiB and ¹⁸F-florbetapir in a Phase 2/3 clinical trial of anti-Aβ monoclonal antibodies.<h4>Methods</h4>Sixty-six mutation-positive participants enrolled in the gantenerumab and placebo arms of the first Dominantly Inherited Alzheime2023-01-01T00:00:00Z2023 Jul2026-05-28T23:12:09.141Z2024-11-09T11:13:25.052ZS-EPMC103301553701773710.1007/s00259-023-06209-0